Immunological aspects of cancer chemotherapy

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1×

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

A cytokine-mediated link between innate immunity, inflammation, and cancer

Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625

A Nanoplatform to Amplify Apoptosis-to-Pyroptosis Immunotherapy via Immunomodulation of Myeloid-Derived Suppressor Cells

Zhou, S., Shang, Q., Ji, J., & Luan, Y. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c16154 · Cited by 74

Genesis and Mechanism of Some Cancer Types and an Overview on the Role of Diet and Nutrition in Cancer Prevention

Kamal, N., Ilowefah, M. A., Hilles, A. R., Anua, N. A., Awin, T. M., Alshwyeh, H. A., Aldosary, S. K., Sahib, N. G., Alosaimi, A. A., Rahman, A., et al. (2022) · Molecules · doi:10.3390/molecules27061794 · Cited by 79

Role of Radiation Therapy as Immune Activator in the Era of Modern Immunotherapy for Metastatic Malignant Melanoma

Okwan-Duodu, D. K., Pollack, B. P., Lawson, D. H., & Khan, M. K. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3182940dc3 · Cited by 73

Dynamic Behavior and Function of Foxp3+ Regulatory T Cells in Tumor Bearing Host

Qin, F. X.-F. (2009) · Cellular and Molecular Immunology · doi:10.1038/cmi.2009.2 · Cited by 74

Dendritic-Tumor Fusion Cell-Based Cancer Vaccines

Koido, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060828 · Cited by 76

Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?

Marino, F. Z., Ascierto, P. A., Rossi, G., Staibano, S., Montella, M., Russo, D., Alfano, R., Morabito, A., Botti, G., & Franco, R. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1309387 · Cited by 71

Tumor Antigen Cross‐Presentation and the Dendritic Cell: Where it All Begins?

McDonnell, A. M., Robinson, B. W. S., & Currie, A. J. (2010) · Journal of Immunology Research · doi:10.1155/2010/539519 · Cited by 75

Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer

Karlsson, M., Marits, P., Dahl, K., Dagöö, T., Enerbäck, S., Thörn, M., & Winqvist, O. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-0920-8 · Cited by 73

Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment

Wang, E., Bussom, S., Chen, J., Quinn, C., Bedognetti, D., Lam, W., Guan, F., Jiang, Z., Mark, Y., Zhao, Y., et al. (2011) · BMC Medical Genomics · doi:10.1186/1755-8794-4-38 · Cited by 72

Immunotherapy for prostate cancer: recent developments and future challenges

Schweizer, M. T., & Drake, C. G. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9479-8 · Cited by 72

Cancer vaccines using supramolecular hydrogels of NSAID-modified peptides as adjuvants abolish tumorigenesis

Wang, Z., Liang, C., Shi, F., He, T., Gong, C., Wang, L., & Yang, Z. (2017) · Nanoscale · doi:10.1039/c7nr04990k · Cited by 71

Phase I study of a chloroquine–gemcitabine combination in patients with metastatic or unresectable pancreatic cancer

Samaras, P., Tusup, M., Nguyen‐Kim, T. D. L., Seifert, B., Bachmann, H., von Moos, R., Knuth, A. K., & Pascolo, S. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3446-y · Cited by 73

Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death

Phung, C. D., Nguyen, H. T., Choi, J. Y., Pham, T. T., Acharya, S., Timilshina, M., Chang, J., Kim, J., Jeong, J., Ku, S., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.047 · Cited by 72

Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype

Ding, Z., Blazar, B. R., Mellor, A. L., Munn, D. H., & Zhou, G. (2010) · Blood · doi:10.1182/blood-2009-11-253336 · Cited by 71

Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival

Brück, O. E., Dufva, O., Hohtari, H. R., Blom, S., Turkki, R., Ilander, M. M., Kovanen, P. E., Pallaud, C., Ramos, P. M., Lähteenmäki, H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000792 · Cited by 71

Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy

Cotechini, T., Atallah, A., & Grossman, A. (2021) · Cells · doi:10.3390/cells10040960 · Cited by 74

Radiotherapy of Human Sarcoma Promotes an Intratumoral Immune Effector Signature

Sharma, A., Bode, B., Studer, G., Moch, H., Okoniewski, M. J., Knuth, A. K., von Boehmer, L., & van den Broek, M. F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0352 · Cited by 70

Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study

Nishida, S., Ishikawa, T., Egawa, S., Koido, S., Yanagimoto, H., Ishii, J., Kanno, Y., Kokura, S., Yasuda, H., Oba, M. S., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0386 · Cited by 71

Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer

Callari, M., Cappelletti, V., D’Aiuto, F., Musella, V., Lembo, A., Petel, F. X., Karn, T., Iwamoto, T., Provero, P., Daidone, M. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0757 · Cited by 69

Role of Nanotechnology in Overcoming the Multidrug Resistance in Cancer Therapy: A Review

Mir, S. A., Hamid, L., Bader, G. N., Shoaib, A., Rahamathulla, M., Alshahrani, M. Y., Alam, P., & Shakeel, F. (2022) · Molecules · doi:10.3390/molecules27196608 · Cited by 76

Innovative nanomaterials for cancer diagnosis, imaging, and therapy: Drug delivery applications

Pourmadadi, M., Eshaghi, M. M., Ostovar, S., Mohammadi, Z. A., Sharma, R. K., Paiva‐Santos, A. C., Rahmani, E., Rahdar, A., & Pandey, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104357 · Cited by 72

The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer

Khong, A., Nelson, D. J., Nowak, A. K., Lake, R., & Robinson, B. W. S. (2012) · International Reviews of Immunology · doi:10.3109/08830185.2012.698338 · Cited by 67

Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials

Natori, A., Ethier, J.-L., Amir, E., & Cescon, D. W. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.024 · Cited by 69

Potentiating prostate cancer immunotherapy with oncolytic viruses

Lee, P. C., & Gujar, S. A. (2018) · Nature Reviews Urology · doi:10.1038/nrurol.2018.10 · Cited by 70

Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles

Silva, C. G. D., Camps, M. G. M., Li, T. M. W. Y., Zerrillo, L., Löwik, C. W. G. M., OSSENDORP, F. A., & Cruz, L. J. (2019) · Theranostics · doi:10.7150/thno.34429 · Cited by 67

Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology

Jan, N., Sofi, S., Qayoom, H., Shabir, A., Haq, B. U., Macha, M. A., Almilaibary, A., & Mir, M. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24670 · Cited by 68

Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model

Roy, A., Singh, M. S., Upadhyay, P. K., & Bhaskar, S. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.045 · Cited by 68

Regular Dose of Gemcitabine Induces an Increase in CD14+ Monocytes and CD11c+ Dendritic Cells in Patients with Advanced Pancreatic Cancer

Soeda, A., Morita‐Hoshi, Y., Makiyama, H., Morizane, C., Ueno, H., Ikeda, M., Okusaka, T., Yamagata, S., Takahashi, N. K., Hyodo, I., et al. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp112 · Cited by 68

Immunological consequences of chemotherapy: Single drugs, combination therapies and nanoparticle-based treatments

Pusuluri, A., Wu, D., & Mitragotri, S. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.020 · Cited by 70

Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis

Cai, H., Wang, C., Shukla, S., & Steinmetz, N. F. (2019) · Advanced Science · doi:10.1002/advs.201802281 · Cited by 67

The effect of miRNA and autophagy on colorectal cancer

Long, J., He, Q., Yin, Y., Lei, X., Li, Z., & Zhu, W. (2020) · Cell Proliferation · doi:10.1111/cpr.12900 · Cited by 69

Immune checkpoint inhibitors in lymphoma: challenges and opportunities

Hatic, H., Sampat, D., & Goyal, G. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6833 · Cited by 69

Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A–Specific, Tumor-Reactive CTL in Melanoma Patients

Palermo, B., Bello, D. D., Sottini, A., Serana, F., Ghidini, C., Gualtieri, N., Ferraresi, V., Catricalà, C., Belardelli, F., Proietti, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1326 · Cited by 67

Targeting chemotherapy-resistant leukemia by combining DNT cellular therapy with conventional chemotherapy

Chen, B., Lee, J. B., Kang, H., Minden, M. D., & Li, Z. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0756-9 · Cited by 67

Antitumor Potential of Immunomodulatory Natural Products

Nuzzo, G., Senese, G., Gallo, C., Albiani, F., Romano, L., d’Ippolito, G., Manzo, E., & Fontana, A. (2022) · Marine Drugs · doi:10.3390/md20060386 · Cited by 66

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

Ladoire, S., Arnould, L., Mignot, G., Apétoh, L., Rébé, C., Martin, F., Fumoleau, P., Coudert, B. P., & Ghiringhelli, F. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.261 · Cited by 72

Integrated PK-PD and agent-based modeling in oncology

Wang, Z., Butner, J. D., Vittorio Cristini, C., & Deisboeck, T. S. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9403-7 · Cited by 69

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors

Zhang, L., Zhou, C., Zhang, S., Chen, X., Liu, J., Xu, F., & Liang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.939249 · Cited by 68

Immunotoxicology: challenges in the 21st century and in vitro opportunities

Härtung, T. (2013) · ALTEX · doi:10.14573/altex.2013.4.411 · Cited by 65

Viral subversion of immunogenic cell death

Kepp, O., Senovilla, L., Galluzzi, L., Panaretakis, T., Schlemmer, F., Madeo, F., Zitvogel, L., & Kroemer, G. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7939 · Cited by 67

Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy

Zhang, C., & Pu, K. (2020) · Small Structures · doi:10.1002/sstr.202000026 · Cited by 65

Immunological off-target effects of standard treatments in gastrointestinal cancers

Duffy, A. G., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt349 · Cited by 63

Significant Impact of Immunogen Design on the Diversity of Antibodies Generated by Carbohydrate-Based Anticancer Vaccine

Yin, Z., Chowdhury, S., McKay, C. S., Baniel, C., Wright, W. S., Bentley, P. A., Kaczanowska, K., Gildersleeve, J. C., Finn, M. G., BenMohamed, L., et al. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00406 · Cited by 64

Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells

Antonangeli, F., Soriani, A., Ricci, B., Ponzetta, A., Benigni, G., Morrone, S., Bernardini, G., & Santoni, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1218105 · Cited by 67

Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity

Mastria, E. M., Cai, L. Y., Kan, M. J., Li, X., Schaal, J. L., Fiering, S., Gunn, M. D., Dewhirst, M. W., Nair, S. K., & Chilkoti, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.021 · Cited by 64

Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8 + T cell activation in the presence of adjuvant temozolomide

Pellegatta, S., Eoli, M., Cuccarini, V., Anghileri, E., Pollo, B., Pessina, S., Frigerio, S., Servida, M., Cuppini, L., Antozzi, C. G., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1412901 · Cited by 64

Nanomedicines guided nanoimaging probes and nanotherapeutics for early detection of lung cancer and abolishing pulmonary metastasis: Critical appraisal of newer developments and challenges to clinical transition

Gao, X., Guo, L., Li, J., Thu, H. E., & Hussain, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.024 · Cited by 62

The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers

Gelsomino, F., Lamberti, G., Parisi, C., Casolari, L., Melotti, B., Sperandi, F., & Ardizzoni, A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.08.003 · Cited by 63

CD4+CD25hiCD127low Regulatory T Cells Are Increased in Oral Squamous Cell Carcinoma Patients

Lim, K. P., Chun, N. A. L., Ismail, S. M., Abraham, M. T., Yusoff, M. N., Zain, R. B., Ngeow, W. C., Ponniah, S., & Cheong, S. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103975 · Cited by 63

Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts

Tseng, C.-W., Trimble, C. L., Zeng, Q., Monie, A., Alvarez, R. D., Huh, W. K., Hoory, T., Wang, M., Hung, C., & Wu, T. ‐. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0596-0 · Cited by 62

Cytokine gene‐mediated immunotherapy: Current status and future perspectives

Jinushi, M., & Tahara, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01202.x · Cited by 61

Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma

Yang, C., Yan, H., Wang, Y., Shi, Y. X., & Dai, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-00859-5 · Cited by 66

Impact of Chemotherapy on Extracellular Vesicles: Understanding the Chemo-EVs

Razak, N. S. A., Mutalib, N. A., Mohtar, M. A., & Abu, N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01113 · Cited by 61

Dendritic cells as cancer therapeutics

Bryant, C. E., Sutherland, S., Kong, B., Papadimitrious, M. S., Fromm, P. D., & Hart, D. N. J. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2018.02.015 · Cited by 61

Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer

Schmidt, E. V. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0714-9 · Cited by 63

Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows

Roberts, P. J., Kumarasamy, V. M., Witkiewicz, A. K., & Knudsen, E. S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1161 · Cited by 62

Radiomic biomarkers of tumor immune biology and immunotherapy response

Wang, J. H., Wahid, K. A., van Dijk, L. V., Farahani, K., Thompson, R. F., & Fuller, C. D. (2021) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2021.03.006 · Cited by 61

Immunogenic tumor cell death promotes dendritic cell migration and inhibits tumor growth via enhanced T cell immunity

Moriya, T., Kitagawa, K., Hayakawa, Y., Hemmi, H., Kaisho, T., Ueha, S., Ikebuchi, R., Yasuda, I., Nakanishi, Y., Honda, T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102424 · Cited by 60

The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation

Hu, J., Kinn, J. M., Zirakzadeh, A. A., Sherif, A. M., Norstedt, G., Wikström, A. C., & Winqvist, O. (2012) · Clinical & Experimental Immunology · doi:10.1111/cei.12060 · Cited by 62

Licensing Adaptive Immunity by NOD-Like Receptors

Liu, D., Rhebergen, A. M., & Eisenbarth, S. C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00486 · Cited by 66

IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery

Qian, S., Zhang, M., Chen, Q., He, Y., Wang, W., & Wang, Z. (2016) · RSC Advances · doi:10.1039/c5ra25046c · Cited by 61

CAR T‐cell immunotherapy: The path from the by‐road to the freeway?

Whilding, L. M., & Maher, J. F. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.012 · Cited by 61

Physically stimulated nanotheranostics for next generation cancer therapy: Focus on magnetic and light stimulations

Thorat, N. D., Tofail, S. A. M., von Rechenberg, B., Townley, H. E., Brennan, G., Silien, C., Yadav, H. M., Steffen, T., & Bauer, J. (2019) · Applied Physics Reviews · doi:10.1063/1.5049467 · Cited by 60

Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma

Farshadi, E. A., Chang, J., Sampadi, B. K., Doukas, M., Land, F. R. V. ‘., van der Sijde, F., Vietsch, E. E., Pothof, J., Koerkamp, B. G., & van Eijck, C. H. J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1681 · Cited by 60

Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization

Nakamoto, Y., Mizukoshi, E., Kitahara, M., Arihara, F., Sakai, Y., Kakinoki, K., Fujita, Y., Marukawa, Y., Kazumori, A. R. A. I., Yamashita, T., et al. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04246.x · Cited by 60

CD11c+ Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors

Haynes, N. M., Hawkins, E. D., Li, M., McLaughlin, N. M., Hämmerling, G. J., Schwendener, R. A., Winoto, A., Wensky, A. K., Yagita∥, H., Takeda, K., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903624 · Cited by 60

Alkylating Agent Melphalan Augments the Efficacy of Adoptive Immunotherapy Using Tumor-Specific CD4+ T Cells

Lu, X., Ding, Z., Cao, Y., Liu, C., Habtetsion, T. G., Yu, M., Lemos, H. D. P., Salman, H., Xu, H., Mellor, A. L., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401894 · Cited by 61

Inflammatory Pathways as Promising Targets to Increase Chemotherapy Response in Bladder Cancer

Zhu, Z., Shen, Z., & Chen, X. (2012) · Mediators of Inflammation · doi:10.1155/2012/528690 · Cited by 60

Sex Steroid Ablation Enhances Hematopoietic Recovery following Cytotoxic Antineoplastic Therapy in Aged Mice

Dudakov, J. A., Goldberg, G. L., Reiseger, J. J., Vlahos, K., Chidgey, A. P., & Boyd, R. L. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900196 · Cited by 60

Molecular mechanisms of curcumins suppressing effects on tumorigenesis, angiogenesis and metastasis, focusing on NF-κB pathway

Panahi, Y., Darvishi, B., Ghanei, M., Jowzi, N., Beiraghdar, F., & Varnamkhasti, B. S. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.12.004 · Cited by 63

Engineering Nanoparticles toward the Modulation of Emerging Cancer Immunotherapy

Wang, S., Sun, Z., & Hou, Y. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000845 · Cited by 60

Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study

Bauer, C. A., Dauer, M., Saraj, S., Schnurr, M., Bauernfeind, F. G., Sterzik, A., Junkmann, J., Jakl, V., Kiefl, R., Oduncu, F. S., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1023-5 · Cited by 59

Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer

Aoki, T., Matsushita, H., Hoshikawa, M., Hasegawa, K., Kokudo, N., & Kakimi, K. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.01.002 · Cited by 59

Synergic Antitumor Effect of Photodynamic Therapy and Chemotherapy Mediated by Nano Drug Delivery Systems

Kiyaseh, M., Zamani, M., Kouchi, F. R., Eixenberger, J. E., Shirini, D., Estrada, D., & Shirini, F. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020322 · Cited by 58

Fish Oil Supplementation Improves Neutrophil Function During Cancer Chemotherapy

Bonatto, S. J. R., de Oliveira, H. H. P., Nunes, E. A., Pequito, D., Iagher, F., Coelho, I., Naliwaiko, K., Kryczyk, M., de Brito, G. A. P., Repka, J. C. D., et al. (2011) · Lipids · doi:10.1007/s11745-011-3643-0 · Cited by 58

Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro.

Kan, S., Hazama, S., Maeda, K., Inoue, Y., Homma, S., Koido, S., Okamoto, M., & Oka, M. (2012) · PubMed · Cited by 58

Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer

Kaewkangsadan, V., Verma, C., Eremin, J. M., Cowley, G., Ilyas, M., & Eremin, O. (2016) · Journal of Immunology Research · doi:10.1155/2016/4757405 · Cited by 60

Immunochemotherapy mediated by thermosponge nanoparticles for synergistic anti-tumor effects

Zhao, Y., Song, Q., Yin, Y., Wu, T., Hu, X., Gao, X., Gao, L., Tan, S., & Zhang, Z. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.037 · Cited by 58

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

de Lara, P. T., Cecconi, V., Hiltbrunner, S., Yagita∥, H., Friess, M., Bode, B., Opitz, I., Vrugt, B., Weder, W., Stolzmann, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1231 · Cited by 60

Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer

Liang, Y., Lü, W., Zhang, X., & Lü, B. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0770-4 · Cited by 58

Extracellular Vesicles and Damage-Associated Molecular Patterns: A Pandora’s Box in Health and Disease

Picca, A., Guerra, F., Calvani, R., Coelho‐Júnior, H. J., Landi, F., Bernabei, R., Romanò, R., Bucci, C., & Marzetti, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.601740 · Cited by 58

Necroptosis-dependent Immunogenicity of Cisplatin: Implications for Enhancing the Radiation-induced Abscopal Effect

Luo, R., Onyshchenko, K., Wang, L., Gaedicke, S., Grosu, A., Firat, E., & Niedermann, G. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1591 · Cited by 61

Perioperative Immunosuppressive Factors during Cancer Surgery: An Updated Review

Bezu, L., Öksüz, D. A., Bell, M., Buggy, D. J., Díaz‐Cambronero, Ó., Enlund, M., Forget, P., Gupta, A. K., Hollmann, M. W., Ionescu, D. C., et al. (2024) · Cancers · doi:10.3390/cancers16132304 · Cited by 59

Apoptotic tumor cells induce IL ‐27 release from human DC s to activate T reg cells that express CD 69 and attenuate cytotoxicity

Sekar, D., Hahn, C., Brüne, B., Roberts, E., & Weigert, A. (2012) · European Journal of Immunology · doi:10.1002/eji.201142093 · Cited by 61

Immuno-oncology-101: overview of major concepts and translational perspectives

Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 60

Chemotherapy Combines Effectively with Anti–PD-L1 Treatment and Can Augment Antitumor Responses

Cubas, R. A., Москаленко, М., Cheung, J., Yang, M. X., McNamara, E., Xiong, H., Hoves, S., Ries, C. H., Kim, J. G., & Gould, S. E. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800275 · Cited by 58

A randomized phase II trial of induction chemotherapy followed by cisplatin chronotherapy versus constant rate delivery combined with radiotherapy

Zhang, P. X., Jin, F., Li, Z.-H., Wu, W.-L., Li, Y., Long, J., Chen, G. Y., Chen, X. X., Gan, J. Y., Gong, X. Y., et al. (2017) · Chronobiology International · doi:10.1080/07420528.2017.1397684 · Cited by 56

“Glowing Head” Mice: A Genetic Tool Enabling Reliable Preclinical Image-Based Evaluation of Cancers in Immunocompetent Allografts

Day, C., Carter, J., Ohler, Z. W., Bonomi, C., Meskini, R. E., Martin, P., Graff‐Cherry, C., Feigenbaum, L., Tüting, T., Dyke, T. V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109956 · Cited by 56

Nanoparticle-based drug delivery systems to overcome gastric cancer drug resistance

Nejati‐Koshki, K., Rastegar, M., Fathi, F., Dadashpour, M., & Arabzadeh, A. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103231 · Cited by 55

Abrogation of Local Cancer Recurrence After Radiofrequency Ablation by Dendritic Cell-based Hyperthermic Tumor Vaccine

Liu, Q., Zhai, B., Yang, W., Yu, L., Dong, W., He, Y., Chen, L., Tang, L., Lin, Y., Huang, D., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.221 · Cited by 55

Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy

Alagkiozidis, I., Facciabene, A., Tsiatas, M. L., Carpenito, C., Benencia, F., Adams, S. F., Jonak, Z., June, C. H., Powell, D. J., & Coukos, G. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-77 · Cited by 55

The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy

Ghiringhelli, F., & Apétoh, L. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865520 · Cited by 54

Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer

Zhu, X., & Lang, J. (2017) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2017.28.e64 · Cited by 56

5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients

Zhang, M., Fan, Y., Che, X., Hou, K., Zhang, C., Li, C., Wen, T., Wang, S., Cheng, Y., Liu, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00492 · Cited by 55

Immunotherapeutic approaches for hepatocellular carcinoma

Longo, V., Gnoni, A., Gardini, A. C., Pisconti, S., Licchetta, A., Scartozzi, M., Memeo, R., Palmieri, V. O., Aprile, G., Santini, D., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15406 · Cited by 54

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

Torres, E. T. R., Ho, W. J., Danilova, L., Tandurella, J. A., Leatherman, J. M., Rafie, C. I., Wang, C., Brufsky, A., LoRusso, P. M., Chung, V. M., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00729-w · Cited by 57

Towards Understanding the Role of Cancer-Associated Inflammation in Chemoresistance

de Visser, K. E., & Jonkers, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788453239 · Cited by 56

Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas

Laimer, K., Troster, B., Kloss, F. R., Schäfer, G., Obrist, P., Perathoner, A., Laimer, J., Brandacher, G., Rasse, M., Margreiter, R., et al. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.03.007 · Cited by 54

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours

Gillessen, S., Gnad-Vogt, U., Gallerani, E., Beck, J., Sessa, C., Omlin, A. G., Mattiacci, M. R., Liedert, B., Kramer, D., Laurent, J., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.07.015 · Cited by 54

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 951

Immune Effects of Conventional Cancer Therapeutics

Demaria, S., & Galluzzi, L. (2018) · Springer Publishing Company eBooks · doi:10.1891/9781617052736.0022

Activation of Immune-Mediated Tumor Cell Death by Chemotherapy

McCoy, M. J., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_14

Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy

Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 88

Immunogenic effects of chemotherapy-induced tumor cell death

Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 328